AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28091501 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with SSRI antidepressants
Number of subjects: 50
Study 25476698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (daily for nine consecutive days on five points, six cycles for a total of 60 days)
Number of subjects: 100
Study 25476698 — intervention group
Group type: COMPARATOR
Intervention: Control group (wearing single-vision corrective lenses)
Number of subjects: 100
Study 22036632 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy
Number of subjects: 734
Study 22036632 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye)
Number of subjects: 734
Study 20538079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Cefazolin
Number of subjects: 450
Study 20538079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 20538079 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 450
Study 17928265 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Moving advertisements
Number of subjects: 31
Study 17928265 — intervention group
Group type: COMPARATOR
Intervention: Standard advertisements (Control)
Number of subjects: 31
Study 16447355 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard face-to-face MDT meetings
Number of subjects: 45
Study 16447355 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine-delivered MDT meetings
Number of subjects: 45
Study 12578932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideomotor apraxia severity based on scores from a verbal gesture-to-command (pantomime) task
Number of subjects: 20
Study 12578932 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 20
Study 10812737 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCE with ACIOL
Number of subjects: 2000
Study 10812737 — intervention group
Group type: COMPARATOR
Intervention: ICCE with aphakic spectacles (Control)
Number of subjects: 2000
Study 8783774 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg orally for 8 days
Number of subjects: 29
Study 8783774 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg with hydrochlorothiazide 12.5 mg or 25 mg for last 4 days
Number of subjects: 29
Study 8783774 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg orally
Number of subjects: 29
Study 1629891 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 1629891 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 1629891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6148867 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with cimetidine
Number of subjects: 12
Study 6148867 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 12
Study 6148867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol with cimetidine
Number of subjects: 12
Study 6148867 — intervention group
Group type: COMPARATOR
Intervention: Nadolol alone
Number of subjects: 12
Study 31257623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tact-Intraverbal (TI) group
Number of subjects: 32
Study 31257623 — intervention group
Group type: COMPARATOR
Intervention: Intraverbal-Tact (IT) group
Number of subjects: 32
Study 31257623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 30284586 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg hydromorphone (2 mL)
Number of subjects: 50
Study 30284586 — intervention group
Group type: COMPARATOR
Intervention: 2 mL normal saline intravenously
Number of subjects: 50
Study 26581682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa beverage containing 320 mg total cocoa flavanols/day
Number of subjects: 0
Study 26581682 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 26581682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa beverage and Placebo beverage
Number of subjects: 0
Study 25876348 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving cupping therapy combined with autohemotherapy with acupoint injection (1 mL at each acupoint, once every 3 days)
Number of subjects: 104
Study 25876348 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine tablets (10 mg once daily) and compound dexamethasone acetate cream (once to twice daily)
Number of subjects: 104
Study 25876348 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving cupping therapy combined with autohemotherapy with acupoint injection
Number of subjects: 104
Study 25876348 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine tablets and compound dexamethasone acetate cream
Number of subjects: 104
Study 22466023 — intervention group
Group type: EXPERIMENTAL
Intervention: brief internet chat introduction
Number of subjects: 60
Study 22466023 — intervention group
Group type: COMPARATOR
Intervention: control internet surfing condition
Number of subjects: 60
Study 20140214 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg FMP2.1 in 0.1 mL AS02(A)
Number of subjects: 100
Study 20140214 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg FMP2.1 in 0.25 mL AS02(A)
Number of subjects: 100
Study 20140214 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg FMP2.1 in 0.5 mL AS02(A)
Number of subjects: 100
Study 20140214 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (RabAvert)
Number of subjects: 100
Study 20140214 — intervention group
Group type: EXPERIMENTAL
Intervention: All malaria vaccine groups
Number of subjects: 100
Study 18997466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 14
Study 18997466 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 14
Study 15824543 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-parent triad approach
Number of subjects: 0
Study 15824543 — intervention group
Group type: COMPARATOR
Intervention: Case-control approach
Number of subjects: 0
Study 12478216 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.80 g/kg)
Number of subjects: 18
Study 12478216 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 18
Study 12478216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10048112 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-tailored intervention
Number of subjects: 843
Study 10048112 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tailored intervention
Number of subjects: 843
Study 10048112 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self-help guide
Number of subjects: 843
Study 10048112 — intervention group
Group type: COMPARATOR
Intervention: No-information control group
Number of subjects: 843
Study 10048112 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help materials (all types)
Number of subjects: 843
Study 7497163 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular invitation to mammographic screening for breast cancer
Number of subjects: 19844
Study 7497163 — intervention group
Group type: COMPARATOR
Intervention: Unscreened control group
Number of subjects: 19844
Study 1970633 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g DS implant
Number of subjects: 12
Study 1970633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) implants
Number of subjects: 12
Study 393242 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system scopolamine (TTS-scopolamine)
Number of subjects: 35
Study 393242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dimenhydrinate
Number of subjects: 35
Study 393242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31048871 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin-gentamicin topical cream
Number of subjects: 399
Study 31048871 — intervention group
Group type: COMPARATOR
Intervention: Paromomycin alone topical cream
Number of subjects: 399
Study 27215856 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional OSA (POSA) patients
Number of subjects: 143
Study 27215856 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-positional OSA (NPOSA) patients
Number of subjects: 143
Study 27215856 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 143
Study 26695356 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cleaning and disinfection interventions using antibacterial products for hand hygiene and surface cleaning or disinfection for one year
Number of subjects: 393
Study 26695356 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cleaning and disinfection interventions
Number of subjects: 393
Study 23329889 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable conduit small gap tubulization for peripheral nerve mutilation
Number of subjects: 0
Study 23329889 — intervention group
Group type: COMPARATOR
Intervention: Traditional epineurial neurorrhaphy
Number of subjects: 0
Study 21953370 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (DES)
Number of subjects: 474
Study 21953370 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional DES
Number of subjects: 474
Study 21953370 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent fracture rate (both DES and BMS)
Number of subjects: 474
Study 18781486 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (52 g of soy protein containing 112 mg of isoflavones)
Number of subjects: 110
Study 18781486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16612397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration in an intensive care unit
Number of subjects: 114
Study 16612397 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline hydration
Number of subjects: 114
Study 12904084 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 12904084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronic acid and zoledronic acid
Number of subjects: 0
Study 12904084 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 0
Study 12904084 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative transplant
Number of subjects: 0
Study 12904084 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with dendritic cells
Number of subjects: 0
Study 11214425 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha 10,000 UI twice a week and 525 mg ferrous sulphate 3 times a day
Number of subjects: 60
Study 11214425 — intervention group
Group type: COMPARATOR
Intervention: 525 mg ferrous sulphate three times a day per os for 3 weeks
Number of subjects: 60
Study 9414541 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical treatments (radical prostatectomy, radical radiotherapy)
Number of subjects: 0
Study 9414541 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (monitoring and treatment of symptoms)
Number of subjects: 0
Study 9414541 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests (DRE, PSA, TRUS, biopsy)
Number of subjects: 0
Study 8017473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 10 to 40 mg/day
Number of subjects: 381
Study 2783678 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol
Number of subjects: 97
Study 2783678 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy plus oral propranolol
Number of subjects: 97
Study 2783678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhepatic sclerotherapy plus oral propranolol
Number of subjects: 97
Study 781848 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate ointment; treated with active drug for three weeks
Number of subjects: 34
Study 781848 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo); treated with placebo for three weeks
Number of subjects: 34
Study 31408838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NO source)
Number of subjects: 81
Study 31408838 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 81
Study 31408838 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold task
Number of subjects: 81
Study 31408838 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation task
Number of subjects: 81
Study 27462804 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-031
Number of subjects: 0
Study 27462804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25012612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3), 0.6 million units i.m. once
Number of subjects: 30
Study 25012612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23819224 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (qi pathway intervention and spinal adjustment)
Number of subjects: 71
Study 23819224 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (acupuncture and Tuina)
Number of subjects: 71
Study 22568666 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline formulation of human albumin (pH 10)
Number of subjects: 10
Study 22568666 — intervention group
Group type: COMPARATOR
Intervention: Neutral formulation of human albumin (pH 7.4)
Number of subjects: 10
Study 22568666 — intervention group
Group type: EXPERIMENTAL
Intervention: All injections (both formulations)
Number of subjects: 10
Study 19125238 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 19
Study 19125238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFRs)
Number of subjects: 397
Study 17702797 — intervention group
Group type: COMPARATOR
Intervention: Hawley retainers
Number of subjects: 397
Study 15138435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 20
Study 15138435 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20
Study 11795346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 11064
Study 11795346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study 9369579 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 9369579 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 22
Study 1565182 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy
Number of subjects: 0
Study 1565182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2579800 — intervention group
Group type: COMPARATOR
Intervention: Repetitive stimulation of the wrist joint
Number of subjects: 0
Study 2579800 — intervention group
Group type: COMPARATOR
Intervention: Cessation of stimuli
Number of subjects: 0
Study 31451436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia and xenon
Number of subjects: 62
Study 31451436 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia only
Number of subjects: 62
Study 29469011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue resistance exercise and head flexion exercise against manual resistance
Number of subjects: 91
Study 29469011 — intervention group
Group type: COMPARATOR
Intervention: Brochure on dysphagia rehabilitation (control group)
Number of subjects: 91
Study 26817880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed plates
Number of subjects: 13
Study 26817880 — intervention group
Group type: COMPARATOR
Intervention: Conventional plates
Number of subjects: 13
Study 24876611 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified CGM receivers
Number of subjects: 10
Study 24876611 — intervention group
Group type: COMPARATOR
Intervention: CGM receivers with numerical values obscured
Number of subjects: 10
Study 24876611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 22160762 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 1504
Study 22160762 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers (control)
Number of subjects: 1504
Study 20847149 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐hr cigarette deprivation
Number of subjects: 63
Study 20847149 — intervention group
Group type: COMPARATOR
Intervention: Smoking as usual (noncigarette deprivation)
Number of subjects: 63
Study 17714375 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (stimulant medication)
Number of subjects: 0
Study 17714375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17714375 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD dyads (general)
Number of subjects: 0
Study 17714375 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD adults
Number of subjects: 0
Study 17714375 — intervention group
Group type: COMPARATOR
Intervention: Normal parent-child dyads
Number of subjects: 0
Study 15969309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy (3 times a week for 3 weeks)
Number of subjects: 0
Study 15969309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low intensity visible light)
Number of subjects: 0
Study 15969309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy
Number of subjects: 0
Study 12028307 — intervention group
Group type: EXPERIMENTAL
Intervention: QLF (Quantitative Light-Induced Fluorescence)
Number of subjects: 12
Study 12028307 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (not exposed to demineralizing solution)
Number of subjects: 12
Study 9809500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous suspension (256 microg once daily)
Number of subjects: 195
Study 9809500 — intervention group
Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray (280 microg twice daily)
Number of subjects: 195
Study 9809500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 7695326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day)
Number of subjects: 232
Study 7695326 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.5 mg/kg of body weight per day)
Number of subjects: 232
Study 2389688 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute inflations (group I)
Number of subjects: 49
Study 2389688 — intervention group
Group type: COMPARATOR
Intervention: 5-minute inflations (group II)
Number of subjects: 49
Study 7457943 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 22
Study 7457943 — intervention group
Group type: COMPARATOR
Intervention: Non-Droperidol
Number of subjects: 22
Study 31702258 — intervention group
Group type: EXPERIMENTAL
Intervention: Single detector optoacoustic tomography using acoustic scattering
Number of subjects: 0
Study 31702258 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration signals from raster scanning a light-absorbing microparticle
Number of subjects: 0
Study 31702258 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularized model-based iterative algorithm
Number of subjects: 0
Study 28804009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (30 g/120 kcal, 140 mL) consumed 3 hours before a buffet meal
Number of subjects: 16
Study 28804009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (30 g/120 kcal, 140 mL) consumed 2 hours before a buffet meal
Number of subjects: 16
Study 28804009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (30 g/120 kcal, 140 mL) consumed 1 hour before a buffet meal
Number of subjects: 16
Study 28804009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (30 g/120 kcal, 140 mL) consumed immediately before a buffet meal
Number of subjects: 16
Study 28804009 — intervention group
Group type: COMPARATOR
Intervention: Control (noncaloric drinks at all time points)
Number of subjects: 16
Study 28804009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein days (total energy intake including preload + test meal)
Number of subjects: 16
Study 25605862 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1102
Study 25605862 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1102
Study 23668423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (caloric restriction and increased physical activity)
Number of subjects: 5095
Study 23668423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5095
Study 21861961 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPAD drape
Number of subjects: 60
Study 21861961 — intervention group
Group type: COMPARATOR
Intervention: No RADPAD drape
Number of subjects: 60
Study 18675970 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen retrieval needle
Number of subjects: 0
Study 18675970 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen retrieval needle
Number of subjects: 0
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg/day
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal D2 occupancy
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrastriatal D2 occupancy
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal D2 blockade
Number of subjects: 14
Study 17077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor side effects
Number of subjects: 14
Study 15321026 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost once-weekly
Number of subjects: 20
Study 15321026 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost once-daily (control)
Number of subjects: 20
Study 12575552 — intervention group
Group type: EXPERIMENTAL
Intervention: indapamide
Number of subjects: 292
Study 12575552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingjiao Jiangya Pill
Number of subjects: 292
Study 12575552 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 292